Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells.

Imanishi S, Takahashi R, Katagiri S, Kobayashi C, Umezu T, Ohyashiki K, Ohyashiki JH.

Oncotarget. 2017 Jul 22;8(41):69906-69915. doi: 10.18632/oncotarget.19436. eCollection 2017 Sep 19.

2.

Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia.

Katagiri S, Tauchi T, Ando K, Okabe S, Gotoh M, Ohyashiki K.

Leuk Res Rep. 2017 Apr 12;7:33-35. doi: 10.1016/j.lrr.2017.04.002. eCollection 2017.

3.

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.

Okabe S, Tauchi T, Tanaka Y, Sakuta J, Ohyashiki K.

Oncotarget. 2016 Aug 16;7(33):53116-53126. doi: 10.18632/oncotarget.10605.

4.

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.

Ohyashiki K, Umezu T, Katagiri S, Kobayashi C, Azuma K, Tauchi T, Okabe S, Fukuoka Y, Ohyashiki JH.

Int J Mol Sci. 2016 Apr 15;17(4):570. doi: 10.3390/ijms17040570.

5.

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.

Okabe S, Tauchi T, Tanaka Y, Sakuta J, Ohyashiki K.

J Hematol Oncol. 2015 Aug 4;8:97. doi: 10.1186/s13045-015-0190-9.

7.

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J.

Haematologica. 2015 Feb;100(2):205-13. doi: 10.3324/haematol.2014.110452. Epub 2014 Oct 24.

8.

Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.

Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH.

Blood. 2014 Dec 11;124(25):3748-57. doi: 10.1182/blood-2014-05-576116. Epub 2014 Oct 15.

9.

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.

Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T, Ohyashiki K.

Drug Des Devel Ther. 2014 Aug 25;8:1151-9. doi: 10.2147/DDDT.S66812. eCollection 2014.

10.

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.

Yoshimoto T, Mizoguchi I, Katagiri S, Tauchi T, Furusawa JI, Chiba Y, Mizuguchi J, Ohyashiki JH, Ohyashiki K.

Oncoimmunology. 2014 May 14;3:e28861. eCollection 2014.

11.

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.

Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K.

J Hematol Oncol. 2014 Apr 28;7:37. doi: 10.1186/1756-8722-7-37.

12.

Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.

Okabe S, Tauchi T, Kimura S, Maekawa T, Kitahara T, Tanaka Y, Ohyashiki K.

PLoS One. 2014 Feb 28;9(2):e89080. doi: 10.1371/journal.pone.0089080. eCollection 2014.

13.

Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.

Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, Katoh T, Kusumoto M, Gemma A, Sakai F, Sugiyama Y, Hatake K, Fukuda Y, Kudoh S.

Cancer Sci. 2014 Feb;105(2):195-201. doi: 10.1111/cas.12335. Epub 2014 Jan 21.

14.

Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells.

Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH.

J Biol Chem. 2013 Nov 29;288(48):34343-51. doi: 10.1074/jbc.M113.480822. Epub 2013 Oct 16.

15.

Transfusion-transmitted hepatitis E in a patient with myelodysplastic syndromes.

Kimura Y, Gotoh A, Katagiri S, Hoshi Y, Uchida S, Yamasaki A, Takahashi Y, Fukutake K, Kiguchi T, Ohyashiki K.

Blood Transfus. 2014 Jan;12(1):103-6. doi: 10.2450/2013.0081-13. Epub 2013 Oct 2. No abstract available.

16.

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, Ohyashiki K.

Cancer Biol Ther. 2014 Feb;15(2):207-15. doi: 10.4161/cbt.26725. Epub 2013 Nov 8.

17.

Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan.

Koh H, Hino M, Ohta K, Iino M, Urase F, Yamaguchi M, Yamanouchi J, Usui N, Yoshida M, Tanimoto M, Ohyashiki K, Urabe A, Tamura K, Kanamaru A, Masaoka T.

J Infect Chemother. 2013 Dec;19(6):1126-34. doi: 10.1007/s10156-013-0634-5. Epub 2013 Jun 28.

18.

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.

Okabe S, Tauchi T, Tanaka Y, Kimura S, Maekawa T, Ohyashiki K.

Cancer Cell Int. 2013 Apr 4;13(1):32. doi: 10.1186/1475-2867-13-32.

19.

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.

Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S, Ohyashiki K.

Blood Cancer J. 2012 Jan;2(1):e53. doi: 10.1038/bcj.2011.51. Epub 2012 Jan 20.

20.

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.

J Clin Oncol. 2012 Mar 10;30(8):820-9. doi: 10.1200/JCO.2011.35.6394. Epub 2012 Feb 13.

Supplemental Content

Loading ...
Support Center